Cybersecurity Incident at Synnovis in UK

EQS-News: SYNLAB AG / Key word(s): Statement
Cybersecurity Incident at Synnovis in UK

04.06.2024 / 20:46 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Cybersecurity Incident at Synnovis in UK

SYNLAB AG ('SYNLAB', FSE: SYAB) confirms that Synnovis, a partnership
between two London-based hospital Trusts and SYNLAB UK & Ireland, was the
victim of a cyber-attack on 3 June 2024.

A taskforce of IT experts from Synnovis and the National Health Service in
UK (NHS England) is working diligently to fully assess the impact the attack
has had, and to take the appropriate action needed. Synnovis is working
closely with NHS Trust partners to minimise the impact on patients and other
service users.

It is an isolated incident to Synnovis with no connection to the
cyber-attack on SYNLAB Italy on 18 April 2024. The rest of the SYNLAB Group
including the other SYNLAB facilities in the UK are not impacted.

Regrettably this is affecting patients, with some activity already cancelled
or redirected to other providers as urgent work is prioritised. Synnovis is
working under high pressure to minimise the impact and update patients and
partners on further developments.

SYNLAB and Synnovis apologize for the impact resulting from this criminal
attack.

- Ends -

For more information:

                  Media contact:                +49 (0) 151 466 938 56
     Diana Tabor, FTI Consulting           (1)media-contact@synlab.com

                                    1. mailto:media-contact@synlab.com
               Investor contact:                 +49 (0) 151 6701 3130
          Etienne Ziller, SYNLAB                      (1)ir@synlab.com

1. mailto:ir@synlab.com
About SYNLAB

  * SYNLAB Group is the leader in medical diagnostic services and specialty
    testing in Europe. The Group offers a full range of innovative and
    reliable medical diagnostics to patients, practising doctors, hospitals
    and clinics, governments and corporates.

  * Providing the leading level of service within the industry, SYNLAB is
    the partner of choice for routine and specialty diagnostics in human
    medicine. The Group continuously innovates medical diagnostic services
    for the benefit of patients and customers.

  * SYNLAB operates in more than 30 countries across four continents and
    holds leading positions in most markets, regularly reinforcing the
    strength of its network through a proven acquisition strategy. More than
    27,000 employees, including over 2,000 medical experts, contribute every
    day to the Group's worldwide success.

  * SYNLAB performed around 600 million laboratory tests and achieved
    revenues of EUR2.64 billion in 2023.

* Ticker symbol: SYAB; ISIN: DE000A2TSL71

* More information can be found on www.synlab.com

SYNLAB - forward looking statements

This document does not constitute or form a part of, and should not be
construed as, an offer for sale or subscription of or solicitation of any
offer to purchase or subscribe for any securities in any jurisdiction.

Statements made in this document may include forward-looking statements.
Forward-looking statements include all statements that are not historical
facts and can be identified by the use of forward-looking terminology such
as the words 'believes', 'expects', 'expected', 'may', 'will', 'would',
'should', 'seeks', 'pro forma', 'anticipates', 'intends', 'plans',
'estimates', 'estimated', or the negative of any thereof or other variations
thereof or comparable terminology, or by discussions of strategy or
intentions. These statements are not guarantees of future actions or
performance and involve risks, uncertainties and assumptions as to future
events that may not prove to be accurate. Actual actions or results may
differ materially from what is expressed or forecasted in these
forward-looking statements. As a result, these statements speak only as of
the date they were made and SYNLAB undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. It should be noted that past
performance is not a guide to future performance. Interim results are not
necessarily indicative of full-year results.


---------------------------------------------------------------------------

04.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SYNLAB AG
                   Moosacher Straße 88
                   80809 Munich
                   Germany
   Phone:          +49 1701183753
   E-mail:         ir@synlab.com
   Internet:       www.synlab.com/
   ISIN:           DE000A2TSL71
   WKN:            A2TSL7
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1918021

End of News EQS News Service
---------------------------------------------------------------------------

1918021 04.06.2024 CET/CEST